|Bid||34.250 x 500|
|Ask||34.260 x 400|
|Day's Range||34.130 - 34.510|
|52 Week Range||24.886 - 36.340|
|PE Ratio (TTM)||104.82|
|Earnings Date||Nov 6, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||34.13|
VENLO, The Netherlands , October 16, 2017 /PRNewswire/ -- QIAGEN N.V. (NASDAQ: QGEN) (Frankfurt: QIA) plans as previously announced to release its report on results for the third quarter and first nine ...
Henry Schein (HSIC) continues to grow on dental and animal health business, thanks to merger and acquisition activity. However, rising costs continue to be a burden on the company's bottom line.
NuVasive's (NUVA) latest receipt of expanded FDA 510(k) approval for PRECICE is likely to fortify its hold in the limb reconstruction and trauma market.
The new 52-week high of Bruker (BRKR) came on the back of several new initiatives, the most recent one being the introduction of the new CE-IVD marked Fungiplex Candida fast diagnostic assay.
Researchers at ASHG 2017 cite value of QIAGEN Sample to Insight solutions in multiple disease areas HILDEN , Germany and GERMANTOWN, Maryland , October 12, 2017 /PRNewswire/ -- QIAGEN N.V. (NASDAQ: QGEN; ...
The market is upbeat about QIAGEN's (QGEN) partnership and co-marketing agreement with CENTOGENE AG to boost its bioinformatics portfolio.
QIAGEN (QGEN) makes another encouraging move to expand its advanced bioinformatics portfolio and add additional capabilities, partners CENTOGENE.
Aiding the analysis of hereditary disorders by integrating genomic and clinical databases HILDEN and ROSTOCK , Germany and GERMANTOWN, Maryland , October 9, 2017 /PRNewswire/ -- QIAGEN (NASDAQ: QGEN; Frankfurt ...
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to QIAGEN NV Here are 5 ETFs with the largest exposure to QGEN-US. Comparing the performance and risk of QIAGEN NV with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)
QIAGEN (QGEN) strengthens its highest revenue grossing segment with the launch of QuantiFERON-TB Gold Plus in the United States.
Categories: Yahoo FinanceGet free summary analysis QIAGEN NV reports financial results for the quarter ended June 30, 2017. Highlights Summary numbers: Revenues of USD 348.99 million, Net Earnings of USD 13.95 million. Gross margins widened from 54.66% to 64.52% compared to the same period last year, operating (EBITDA) margins now 33.14% from 24.51%. Change in operating cash ... Read more (Read more...)
Novel CD4/CD8 design delivers most comprehensive evaluation of patients' immune response to tuberculosis infection GERMANTOWN, Maryland and HILDEN, Germany , October 5, 2017 /PRNewswire/ -- QIAGEN (NASDAQ: ...
Assuring the highest accuracy in human identity testing for law enforcement and other uses HILDEN , Germany and GERMANTOWN, Maryland , October 2, 2017 /PRNewswire/ -- QIAGEN (NASDAQ: QGEN; Frankfurt Prime ...
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for QIAGEN NV. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bullish 50 ... Read more (Read more...)
HILDEN, Germany and GERMANTOWN, Md. and BRIDGEWATER, N.J., Aug. 21, 2017-- QIAGEN and Clinical Genomics, a private company developing evidence-based diagnostic tools for colorectal cancer, today announced ...
Convenient blood test uses novel technology to test for recurrence of tumors by detecting circulating DNA HILDEN , Germany , GERMANTOWN, Maryland and BRIDGEWATER, New Jersey , August 21, 2017 /PRNewswire/ ...
Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives QIAGEN NV a score of 44. Our analysis is based on comparing QIAGEN NV with the following peers – Thermo Fisher Scientific Inc., Genomic Health, Inc., Hologic, Inc., Becton, Dickinson and Company, General Electric Company, Trovagene, Inc., Bio-Techne Corporation and GenMark Diagnostics, Inc. (TMO-US, GHDX-US, HOLX-US, BDX-US, ... Read more (Read more...)